Summary:
A phase III, randomized, observer blind, controlled study to demostrate the effectiveness, immunogenicity and safety fo GSK's menigococcal vaccine (MenABCWY) vs. 2 FDA approved vaccines (Bexsero & Menveo) administered to healthy adolescents and young adults.
Qualified Participants Must:
• Be between, and including, 10 - 25 years of age
•
Never have had Meningitis
Qualified Participants May Receive:
Access to a Doctor throughout the entire trial. A full physical exam, complete with all of the blood work and diagnostic testing that you need, and the opportunity to receive a vaccine against menigitis. All of this is provided to you at no cost; in fact, the Pharmaceutical Sponsor may pay you $525.00 for your time and travel once you are enrolled into the study.